DDX41 and Alzheimer disease: As longer Aβs aggregate into amyloid fibrils and other assemblies more readily than the shorter ones, regulation of γ-secretase processivity is a critical determinant of AD risk and remains a viable alternative to inhibition of γ-secretase or β-secretase as an AD therapeutic strategy.